A case of graft-versus-host disease (GvHD) affecting the liver complicating an autologous peripheral blood stem cell transplant for relapsed Hodgkin's disease is described. A brief discussion of the presentation, management and pathology of the condition is included and the importance of including this condition in the differential diagnosis of post transplantation hepatic dysfunction, with consideration of liver biopsy, is emphasized.
Graft-versus-host disease after autologous stem cell transplantation is well described, and can occur either as an unintentional side effect of treatment or intentionally with the post transplant use of immunosuppression 1, 2 (principally cyclosporin) in an effort to exert a graftversus-malignancy effect. The disease process in these induced and sporadic GvHD cases is usually limited to the skin and has a self-limiting course. We describe a case of isolated hepatic GvHD complicating an autologous stem cell transplant for relapsed Hodgkin's disease that required immunosuppressive treatment.
A 31-year-old man presented with supraclavicular lymphadenopathy and night sweats. Biopsy and imaging confirmed a diagnosis of stage 2B nodular sclerosing Hodgkin's disease, with extensive mediastinal involvement. He was enrolled on the LY09 protocol and received six courses of ABVD (adriamycin, busulphan, vincristine, dexamethasone) chemotherapy with complete clinical and radiological remission achieved. Four years after completing treatment, para-tracheal and right hilar lymphadenopathy was noted on routine follow-up chest X-ray, which was quickly followed by symptoms of relapse (night sweats and weight loss). Mediastinoscopy with biopsy confirmed a mediastinal relapse of his Hodgkin's disease. As treatment for this relapse he received two courses of ESHAP (etoposide, cisplatin, cytarabine, methylprednisolone) chemotherapy (again with complete symptomatic and radiological response), and had a peripheral stem cell harvest following the second course of treatment. A good CD34 25 ) and a CRP of 128.7 mg/l. At this time the patient also started to experience abdominal discomfort and anorexia, symptoms that had initially improved as he had recovered from his mucositis. As initial management, potentially hepatotoxic drugs were stopped (fluconazole and aciclovir), but when LFTs continued to worsen alternative diagnoses were sought. The differential diagnosis included veno-occlusive disease of the liver and fungal, viral and bacterial infections. Ultrasound, CT and Doppler studies did not reveal any structural or hepatic vessel abnormalities and LFT improvement did not occur with systemic anti-fungal therapy (liposomal amphotericin B). PCR testing for EBV, CMV and adenovirus did not demonstrate active infection and serology for hepatitis A/B/C and toxoplasmosis demonstrated no current or past infection (confirming blood transfusion tests pre-stem cell harvest). Autoantibody screening, transferrin saturation, serum caeruloplasmin and 24 h copper excretion was also normal. The patient remained apyrexial throughout and with no blood culture evidence of bacterial infection.
A referral was made to gastroenterology and a percutaneous liver biopsy taken. Histological examination of six portal tracts was performed. Abnormalities found included focal bile duct injury (biliary epithelial vacuolation with lymphocytic infiltration) and evidence of a mild hepatitis with occasional eosinophils (Figure 1 ). These findings were consistent with GvHD of the liver, an extremely unusual finding in the autologous transplant setting.
The LFTs continued to deteriorate (alkaline phosphatase 395 U/l, ALT 287 U/l, AST 214 U/l, GGT 367 U/l, bilirubin 155 mmmol/l, CRP 68.5 mg/l) with no improvement in symptoms, over the following 14 days. On the basis of the presumptive diagnosis of hepatic GvHD, methylprednisolone at a dose of 1 gram per day was administered for 4 consecutive days, followed by oral prednisolone starting at 30 mg per day with a slow taper to zero over the next 2 months. Clinical improvement was rapid, with the LFT abnormalities resolving over the next 36 days. Upon the cessation of steroids no further LFT abnormalities developed.
The findings of bile duct apoptosis on liver biopsy with a predominantly cholestatic pattern of LFT abnormalities are typical of GvHD affecting the liver. 3 GvHD post autologous transplantation usually affects the skin, and hepatic GvHD is an unusual complication in this setting. Similar histological findings can result from other disease processes. These include the transfusion of viable lymphocytes in non-irradiated blood products that can lead to transfusion-associated GvHD in patients with Hodgkin's disease and in the post transplant setting. 4, 5 A review of blood bank records excluded exposure to non-irradiated blood products before the patient's transplant. Cholestatic changes on liver biopsy have also been reported as a nonspecific reaction complicating extra-hepatic Hodgkin's disease. 6 Our patient was in complete clinical and radiological remission before transplantation and therefore this would be an unlikely cause for the abnormalities demonstrated in the liver. The underlying pathogenesis of GvHD following autologous stem cell transplantation is uncertain, but is thought to be a consequence of a failure to delete auto-reactive T-cells during immune reconstitution, with the preparative chemotherapy eliminating mature regulatory T-cells. This failure to delete autoreactive Tcells provides an environment in which these lymphocytes can be become activated resulting in GvHD. 7 The effector cells in therapeutically induced autologous GvHD are CD8 þ T-cells that recognize MHC II-expressed antigens in association with a peptide from the invariant chain (CLIP). 8 The pathology underlying induced GvHD may differ from the case described, as the site of major organ involvement is different (skin as opposed to hepatic) and no exposure to immunosuppressive drugs occurred in our case.
Isolated GvHD of the liver has previously been reported 9 and should be included in the differential diagnosis of hepatic dysfunction post-autologous transplant because the treatment of the more common causes of hepatic dysfunction in this setting (the commonest being drug effects and infection), 10 are radically different. Definitive diagnosis is provided by histology obtained by liver biopsy, which does have a significant morbidity and occasional mortality. 11 Autologous GvHD of the upper gastrointestinal (GI) tract has also been described, and if the patient also has symptoms suggestive of this diagnosis (principally nausea and vomiting) 12 an upper GI biopsy may be a safer alternative to liver biopsy in this setting. In patients with isolated liver dysfunction the diagnostic approach should be the exclusion of the more common causes of liver dysfunction in the post-autologous transplant setting, but to be aware of this unusual cause of hepatic dysfunction in this group of patients, with consideration of liver biopsy in selected cases. Figure 1 Portal tract bearing lymphocytic infiltration and in which the bile duct shows epithelial injury with intra-epithelial lymphocytes.
